The top news to come out of skin cancer coverage this year for MHE focused on blood or marrow transplant recipients ...
Leyla O. Shune, MD, describes the available treatment options for patients with chronic graft-versus-host disease who are ...
Patient enrolment has been completed in Cynata's Phase 2 clinical trial of CYP-001 in acute graft versus host disease. The study has enrolled a total of 65 participants in the US, Europe and Australia ...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
During a live event, Hannah Choe, MD, analyzed key findings from the AGAVE-201 trial of axatilimab in chronic graft-vs-host disease. A significant number of patients who develop chronic graft-vs-host ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback